Therapeutic Approach
HERVs as a source
of tumor antigens
Human endogenous retroviruses (HERVs) represent a significant part of the human genome. HERVs are kept silent by epigenetic regulation but can be reactivated by malignant transformation or epigenetic therapies.
HERVs represent a reservoir of targetable antigens, especially in tumors with a low or moderate mutational burden.
Because HERV-derived antigens are seen as foreign, « virus-like » antigens, by the immune system, they represent relevant targets for the development of new cancer vaccines or T cell based therapies.
Our Pipeline
Our Breakthrough immunotherapies, combining cancer vaccines and T-cell therapie, have the potential to address high medical needs in oncology.
| CANCER VACCINE | Discovery & Target validation |
Pre-Clinical | Clinical |
| CANCER VACCINE | Discovery &Target validation |
Pre-Clinical | Clinical |
| TCR T CELLS | Target validation | Pre-Clinical | Clinical | – |
| TCR T CELLS | Target validation | Pre-Clinical | Clinical | – |
Collaborations & Partnerships
Partnerships with
world-class institutions
ErVaccine Technologies established strong partnerships with world-class institutions, to support its scientific innovation and development strategies, including @CRCL/Centre Léon Bérard “Development of immunotherapies targeting non-conventional tumor antigens” directed by Prof. Stéphane Depil.
To leverage ErVaccine development, a collaboration with Complete Omics (Baltimore, USA), a pioneer in proteomics, was launched on a neoantigen validation and quantification project in June 2021.